Author:
Piubelli Chiara,Valerio Matteo,Verzè Matteo,Nicolis Fabrizio,Mantoan Carlotta,Zamboni Sonia,Perandin Francesca,Rizzi Eleonora,Tais Stefano,Degani Monica,Caldrer Sara,Gobbi Federico Giovanni,Bisoffi Zeno,Gori Stefania
Abstract
IntroductionCancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatment. In solid tumor patients an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose.MethodsIn our study we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies.Results and DiscussionOur analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage or type of anticancer treatment.
Reference31 articles.
1. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the veneto oncology network: The rete oncologica veneta covID19 study;Guarneri;Eur J Cancer Oxf Engl 1990.,2021
2. Clinical profile and mortality of sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-sep 2020; sep 2020-may 2021) in the veneto oncology network: The ROVID study;Dieci;Eur J Cancer Oxf Engl 1990.,2022
3. Vaccinazione anti SARS-CoV2/COVID-19. estensione dell’intervallo tra le due dosi dei vaccini a mRNA2021
4. Trasmissione parere del CTS in merito alla estensione dell’intervallo tra le due dosi dei vaccini a mRNA e alla seconda dose del vaccino vaxzevria2021
5. Aggiornamento parere CTS vaccini2021